Absci (NASDAQ:ABSI – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Zacks reports. The firm had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%.
Absci Trading Down 4.0 %
Absci stock opened at $3.08 on Wednesday. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci has a 12 month low of $2.45 and a 12 month high of $6.72. The company’s fifty day simple moving average is $3.87 and its 200-day simple moving average is $3.68. The stock has a market cap of $353.76 million, a P/E ratio of -3.31 and a beta of 2.09.
Analyst Upgrades and Downgrades
Several research firms have issued reports on ABSI. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Absci in a report on Friday, January 17th. KeyCorp dropped their price target on Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of Absci in a report on Tuesday, December 3rd. Finally, Needham & Company LLC began coverage on Absci in a report on Wednesday, January 22nd. They issued a “buy” rating and a $9.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.57.
Absci Company Profile
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Further Reading
- Five stocks we like better than Absci
- How to Calculate Return on Investment (ROI)
- Delta’s Stock Takes a Hit—Can Lower Oil Prices Fuel a Comeback?
- What is diluted earnings per share (Diluted EPS)?
- 3 Hot Stock Upgrades as Analysts Look Ahead to Q2 Earnings
- What is a Low P/E Ratio and What Does it Tell Investors?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
